Shots:
- J&J has reported P-II (RedirecTT-1) trial data on Talvey (talquetamab-tgvs) + Tecvayli (teclistamab-cqyv) in 90 heavily pretreated r/r MM pts with extramedullary disease, where 84.4% were triple-class refractory, 35.6% penta-drug refractory, 20% had prior BCMA CAR-T, & 8.9% had prior bsAb exposure
- Trial showed a 78.9% ORR, with 54.4% achieving CR or better, incl. high responses in pts previously treated with BCMA CAR-T (83.3% ORR) or anti-FcRH5 bsAbs (75% ORR)
- At data cutoff, 66.2% responders remained in response, with mFU of 13.4mos.; 61% were progression-free & alive at 1yr., 64.1% maintained response (mDoR: 13.8mos.), & 74.5% were alive at 1yr., with mOS not yet reached. Data was shared at EHA 2025
Ref: Johnson & Johnson| Image: Johnson & Johnson| Press Release
Related News:- Johnson & Johnson Presents P-IIIb (APEX) Trial Findings of Tremfya for Active Psoriatic Arthritis at EULAR 2025
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
